Gore Range Capital

Gore Range Capital LLC is a venture capital firm established in 2015 and headquartered in New York, New York. The firm specializes in seed, startup, and early venture investments primarily within the healthcare sector, focusing on areas such as biotechnology, therapeutics, life sciences, medical devices, and skin health. Gore Range Capital seeks to invest in companies with strong growth potential and exceptional management teams, typically committing between $0.5 million and $5 million in venture-stage healthcare businesses. The firm emphasizes a hands-on investment approach, blending operational insights with early-stage guidance, and it prefers to take a lead or co-lead role in its investments. By leveraging its domain expertise and extensive industry networks, Gore Range Capital aims to support the success of its portfolio companies, particularly in North America and Western Europe.

Frank DeBernardis

Operating Partner

Chidi Nwankpa, MD

Principal

Past deals in Skincare

Palvella Therapeutics

Post in 2024
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Palvella Therapeutics

Series D in 2023
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.